ArticleFrontiers in immunology2026
Anti-angiotensin II type 1 receptor autoantibodies of IgG3 subclass outperform total anti-AT1R IgG1-IgG4 levels in predicting transplanted kidney antibody-mediated rejection.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding the role of non-HLA antibodies in kidney transplantation: a literature review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-mediated rejection (AMR) is a leading cause of kidney allograft loss. Anti-angiotensin II type-1 receptor (AT1R) autoantibodies (AABs) have been implicated in AMR and microvascular inflammation (MVI), particularly in C4d-negative and non-HLA antibody dependent cases. Conventional assays measure only total IgG and do not assess pathogenic subclass heterogeneity. Whether IgG1-IgG4 subclass profiling improves AMR prediction has not yet been investigated. Methods: We included 143 adult kidney-transplant recipients who underwent indication biopsy between 2018 and 2025. Histopathology was classified according to Banff 2017-2022 criteria. Serum samples were analysed for total AT1R-IgG (U/mL) and AT1R IgG1-IgG4 subclasses (relative optical density). Associations with AMR were assessed using group comparisons, correlation analysis, logistic regression, ROC AUC, and quartile-based analyses. Results: AT1R-IgG3 levels were significantly elevated in AMR (Kruskal-Wallis, p = 0.0396), correlated with AMR (Spearman ρ = 0.19, p = 0.02), and demonstrated better predictive performance (AUC 0.63 vs 0.53) than total AT1R-IgG. Logistic regression showed stronger associations for IgG3 (OR 1.33, p = 0.0004) than total AT1R-IgG (OR 1.19, p = 0.029). AMR prevalence increased across IgG3 quartiles (Q1:10.5% → Q4:31.6%), while no such trend was observed for total AT1R-IgG. Conclusions: AT1R antibodies of IgG3 subclass outperform total AT1R levels in predicting AMR, revealing pathogenic antibody patterns that are not detectable through global IgG quantitation. Subclass profiling may contribute to more precise AMR risk assessment, but longitudinal and multicentre validation studies with standardized subclass-specific assays are needed to confirm these findings. Although AT1R IgG3 levels were significantly correlated with AMR, the magnitude of these associations is insufficient to support their use as an independent diagnostic marker and may only serve as a complementary AMR marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.